Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Clin Pathol. 2014 Sep;142(3):292-8. doi: 10.1309/AJCP73QSLLYDEGXK.

Loss of blast heterogeneity in myelodysplastic syndrome and other chronic myeloid neoplasms.

Author information

1
From the Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN. jevremovic.dragan@mayo.edu.
2
From the Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN.

Abstract

OBJECTIVES:

Flow cytometry immunophenotyping has been suggested as an adjunctive technique in the evaluation of myeloid malignancies, especially in the myelodysplastic syndromes. However, its use has been limited due to complexity and cost restraints. The goal of this study is to attempt a simpler approach to flow cytometry immunophenotyping in myeloid neoplasms.

METHODS:

We analyzed bone marrow specimens of 45 selected patients and an additional 99 consecutive random patients using a limited antibody panel.

RESULTS:

Normal CD34-positive blasts show a characteristic pattern of CD13/HLA-DR expression, with three readily identifiable subpopulations. In contrast, myeloid neoplasms frequently show loss of this heterogeneity.

CONCLUSIONS:

Analysis of a limited antibody panel with a focus on CD13/HLA-DR expression provides relatively high specificity and sensitivity for the detection of myeloid neoplasms.

KEYWORDS:

Blasts; Flow cytometry; MDS

PMID:
25125617
DOI:
10.1309/AJCP73QSLLYDEGXK
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center